Combination therapy for osteoporosis with estrogen, fluoride, and calcium.
Nine women with postmenopausal spinal osteoporosis were treated with combination therapy consisting of estrogen, fluoride, and calcium. Their data were compared with those of a control group treated with fluoride, and calcium without estrogen. Bone mass was measured about every six months by photon absorptiometry (bone mineral content/bone width (BMC/BW)] and total-body neutron activation analysis [total-body calcium (TB Ca)]. Time-trend analysis revealed positive slopes for TB Ca (P = 0.002) and BMC/BW (P = N.S.) for the combination therapy group. The change in BMC/BW in the combination therapy group was significantly different from the response in the fluoride - calcium group. These data suggest that combination therapy may be successful in increasing bone mass in postmenopausal osteoporosis. A clinical trial to establish efficacy and examine risk/benefit ratios should be performed.
D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000032:analysis; D002118:Calcium / Q000008:administration & dosage* / Q000032:analysis; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005459:Fluorides / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D008903:Minerals / Q000032:analysis; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D011188:Potassium / Q000032:analysis
D004967:Estrogens; D008903:Minerals; D005459:Fluorides; D011188:Potassium; D002118:Calcium